Novo Nordisk Wegovy pill sees strong early uptake with over eighteen thousand prescriptions
The oral version of Novo Nordisk's weight loss drug saw 18,410 U.S. prescriptions in its first full week. This performance tracks ahead of other GLP-1 launches.
Insights:
Novo Nordisk A/S has recorded 18,410 prescriptions in the US 
USduring the first full week following the January 5, 2026, launch of its Wegovy pill formulation. According to IQVIA data shared by an analyst on Friday, January 23, 2026, the medication recorded 3,071 U.S. prescriptions in the first four days after launch. Guggenheim analysts noted that this performance is tracking ahead of other GLP-1 receptor agonist market launches, marking a strong start for the first-mover treatment.
USduring the first full week following the January 5, 2026, launch of its Wegovy pill formulation. According to IQVIA data shared by an analyst on Friday, January 23, 2026, the medication recorded 3,071 U.S. prescriptions in the first four days after launch. Guggenheim analysts noted that this performance is tracking ahead of other GLP-1 receptor agonist market launches, marking a strong start for the first-mover treatment.The positive data contributed to a 2.5% rise in shares for Novo Nordisk A/Son Friday, reaching their highest point since late July. This peak coincides with when Mike Doustdar mike doustdartook the reins as the new chief executive officer. The stock has gained approximately 25% throughout January, signaling a recovery as the company moves past the profit warnings and slowing growth it experienced in 2025.
